Minireview: Gut peptides: targets for antiobesity drug development?
about
Interaction between gastric and upper small intestinal hormones in the regulation of hunger and satiety: ghrelin and cholecystokinin take the central stageCentral and peripheral molecular targets for antiobesity pharmacotherapy.Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.Regulation of appetite to treat obesity.New advances in models and strategies for developing anti-obesity drugs.Protein Digestion-Derived Peptides and the Peripheral Regulation of Food Intake.Marine Peptides as Potential Agents for the Management of Type 2 Diabetes Mellitus-A ProspectObesity pharmacotherapy: what is next?Sizing up pharmacotherapy for obesitySensitivity to the satiating effects of exendin 4 is decreased in obesity-prone Osborne-Mendel rats compared to obesity-resistant S5B/Pl rats.The role of hypothalamic estrogen receptors in metabolic regulation.Current and future drug targets in weight managementGut-Brain Endocrine Axes in Weight Regulation and Obesity PharmacotherapySmall lipidated anti-obesity compounds derived from neuromedin U.Reduced plasma level of diazepam-binding inhibitor (DBI) in patients with morbid obesity.Current and emerging therapies for the management of functional gastrointestinal disorders.Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X/A-like cells: role as regulators of food intake and body weight.From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation.Neuroendocrine control of metabolism.Do we need anti-obesity drugs?The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.Food ingredients as anti-obesity agents: a review.Insulin-Producing Cells in the Drosophila Brain also Express Satiety-Inducing Cholecystokinin-Like Peptide, Drosulfakinin.Alterations in circadian and meal-induced gut peptide levels in lean and obese rats.
P2860
Q24617383-058C3AB9-F0E1-4133-8A35-DEA7C10624ABQ30388865-85880AC7-6209-4855-A47E-1369FB6CEB41Q30399390-DD38B5A7-9916-42CE-8C70-8F3B270C02B2Q30403705-4BF77C40-B786-4A74-9E65-3A255654A392Q30429816-9E7F8467-02E4-463A-86F3-05FE19551954Q33593471-2266DE18-5FD8-4B81-BAF1-70B0A9C1020FQ33612142-8066EF7E-83FC-4720-ABDB-AB8E986F8E93Q33827988-F1C4C590-A08E-4CF0-A72F-A4EECBC7A58AQ33969368-C709B6D8-6324-48C8-90C1-D3DF1EA3B26AQ34020617-513E370F-6A0B-4376-AF67-1535D7121A55Q34243150-54839F3F-5291-4ABB-A980-4D6330A28A75Q35089784-4743DE57-4A9D-4D4E-8726-E6629CDD9EDDQ35667150-CFA3DD53-0C85-4224-B2C9-85385F17F37BQ35708420-F8C14F04-E117-4153-AFD1-6B0240BEAB4DQ35882421-5603EC8F-FDDD-4A38-A59F-BBC2C79FC699Q36443725-1E66FAC3-9BAA-4746-9705-7EAB3E016654Q37640221-AD522F47-F332-4C57-9DD6-5304090DBF15Q37690695-123961C3-F1C5-4EFF-BAA6-7533340D9160Q37991003-7DE427C9-23CC-499C-A558-B74BB20E0092Q38071006-C08D6D2C-1288-4222-8915-E8F4EE29D838Q38101677-1BC6F534-9B4C-4725-B9D7-36C910FE8448Q38114511-F58CFFD2-33E6-40CA-952A-7D184B828D3FQ42175077-31729151-87F2-48C2-82DF-AB78536B15D2Q48208276-D4E541C7-65AD-4203-A95C-DC3DD029FFBD
P2860
Minireview: Gut peptides: targets for antiobesity drug development?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Minireview: Gut peptides: targets for antiobesity drug development?
@en
Minireview: Gut peptides: targets for antiobesity drug development?
@nl
type
label
Minireview: Gut peptides: targets for antiobesity drug development?
@en
Minireview: Gut peptides: targets for antiobesity drug development?
@nl
prefLabel
Minireview: Gut peptides: targets for antiobesity drug development?
@en
Minireview: Gut peptides: targets for antiobesity drug development?
@nl
P2860
P356
P1433
P1476
Minireview: Gut peptides: targets for antiobesity drug development?
@en
P2093
Megan J Dailey
Timothy H Moran
P2860
P304
P356
10.1210/EN.2009-0003
P407
P577
2009-04-16T00:00:00Z